A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Recruiting
Phase 1
Interventional Study
Hemodialysis Subjects With Secondary Hyperparathyroidism
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 6 (estimated)
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
MT1013 is a first-in-class dual-target agonist.This study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of \[14C\] MT1013.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 1\. Male or postmenopausal female participants, aged 18 years or older, with a confirmed diagnosis of SHPT.
* 2\. The BMI is between 18 kg/m2 and 35 kg/m2;
* 3\. The subjects must undergo regular maintenance hemodialysis three times a week for at least three months;
* 4\. With…
Contacts